PVR and cancer: CD226-deficient NK cells exhibit impaired tumor control due to shortened contact durations with cancer cells and reduced cytotoxicity, and antibodies blocking CD226-CD155 interactions suppress NK cell-mediated cytotoxicity [30,35].